[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-370105-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-370105-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","mtor-levels-and-metastasis-in-luminal-breast-cancer-implications-for-prognosis-and-treatment","mTOR Levels and Metastasis in Luminal Breast Cancer - Implications for Prognosis and Treatment","","Breast cancer remains the leading cause of cancer mortality in women, largely driven by metastasis. This study investigates the association between serum mammalian target of rapamycin (mTOR) levels and metastasis across luminal breast cancer subtypes, focusing on HER2-positive and HER2-negative groups. A preliminary cross-sectional design measures serum mTOR by Human ELISA, identifies an optimal ROC cut-off, and tests relationships with metastasis using statistical association methods. Findings show strong discriminatory performance and significant linkage between elevated mTOR and metastasis, especially in HER2-positive cases.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/mtor-levels-and-metastasis-in-luminal-breast-cancer-implications-for-prognosis-and-treatment/370105/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/mtor-levels-and-metastasis-in-luminal-breast-cancer-implications-for-prognosis-and-treatment/370105.png","ImageObject",300,407,{"name":42,"@type":43},"acoobca","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-02","2026-09-23",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",10,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What is the study’s primary purpose regarding mTOR?","Question",{"text":63,"@type":64},"To assess the relationship between serum mTOR levels and metastasis in luminal breast cancer subtypes and evaluate mTOR as a predictive biomarker and potential therapeutic target.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How were serum mTOR levels measured and how was the cut-off determined?",{"text":68,"@type":64},"Serum mTOR levels were measured using a Human ELISA kit, and the optimal cut-off was determined using ROC curve analysis.",{"name":70,"@type":61,"acceptedAnswer":71},"What results link mTOR levels to metastasis?",{"text":72,"@type":64},"Elevated serum mTOR levels (≥13.32 ng/mL) were significantly associated with metastasis (p\u003C0.001), with particularly higher mTOR levels observed in HER2-positive cases.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},370105,1790217137,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,115,120,123,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":112,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":113,"slug":114},8,30,"research-report",{"id":116,"doc_module":4,"doc_module_name":25,"category_name":117,"show_sort_weight":118,"slug":119},9,"Religion & Spirituality",20,"religion-spirituality",{"id":118,"doc_module":4,"doc_module_name":25,"category_name":121,"show_sort_weight":118,"slug":122},"World Cup","world-cup",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":55,"slug":125},"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":112,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":102,"language":139,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":12,"update_tm":143,"read_time":144,"preview_page_count":33,"preview_urls":145},3985747870733,"https://ap-avatar.wpscdn.com/davatar_a8503ba1806abce46bf441b54a3ca4cd","RESEARCH ARTICLE  \n\n| Editorial Proc | ess: Submission:02/24/2025 Acceptance:09/06/2025 Published:09/12/2025 |\n| --- | --- |\n\nmTOR Levels and Metastasis in Luminal Breast Cancer: Implications for Prognosis and Treatment  \nMaryam Mayidah Hasan Nur1, Prihantono Prihantono2,3,4 *, Muhammad Ihwan Kusuma1,3, Indra Indra2, Salman Ardi Syamsu2,4, Nilam Smaradhania2,4, John Pieter Jr2, Muhammad Faruk1,4  \nAbstract  \nBackground: Breast cancer (BC) is the most common cancer in women, with metastasis being the leading cause of mortality. The PI3K/PTEN/Akt/mTORC1 signaling pathway plays a crucial role in cancer cell proliferation, angiogenesis, and invasion, with mammalian target of rapamycin (mTOR) serving as a key regulator. Activation of mTOR is associated with tumor growth and resistance to therapy in luminal and human epidermal growth factor receptor 2 positive (HER2-positive) BC subtypes. This study aims to explore the relationship between serum mTOR levels and metastasis in luminal, HER2-positive and HER2-negative BC subtypes to assess the potential of mTOR as a predictive biomarker and therapeutic target. Methods: This preliminary cross-sectional study included BC patients with luminal HER2-positive or HER2-negative subtypes. Serum mTOR levels were measured using a Human ELISA kit. The optimal cut-off point for mTOR was determined using a Receiver Operating Characteristic (ROC) curve analysis. Statistical associations between mTOR levels and metastasis were performed using the Chi-square or Fisher’s exact test, and the prevalence ratio (PR) with a 95% confidence interval was calculated. Results: The ROC curve demonstrated an AUCof 0.996, with an optimal cut-off point for serum mTOR levels at 13.32 ng/mL, showing 100% sensitivity and 96.4% specificity for predicting metastasis. The mean mTOR level was 58.39±250.91 ng/mL, with 50% exhibiting elevated levels (≥13.32 ng/mL). Notably, mTOR levels were significantly higher in HER2-positive cases (113.59±381.87 ng/mL) compared to HER2-negative cases (17.45±14.83 ng/mL; p=0.040). Elevated mTOR levels were significantly associated with metastasis (p\u003C0.001), with a PR of 0.037 (95% CI: 0.005-0.253) . Conclusions: Increased serum mTOR levels (≥13.32 ng/mL) are significantly linked to the presence of metastasis, particularly in HER2-positive BC. These findings suggest serum mTOR as a promising biomarker for metastasis risk and a potential therapeutic target in luminal BC.  \nKeywords: Metastasis-mTOR-HER2-biomarker-breast cancer  \nAsian Pac J Cancer Prev, 26 (9), 3347-3352  \nIntroduction  \nBreast cancer (BC) is the most common type of cancer among women, with a global incidence of 2.3 million cases in 2020 and a mortality rate of 685,000 deaths [1] . While the incidence of BC is higher in developed countries, mortality rates are, paradoxically, greater in developing nations [2] . Risk factors for BC include reproductive, hormonal, and lifestyle factors. Increased early detection through mammography screening has contributed to higher diagnosis rates in developed countries [3] .  \nBased on molecular characteristics, BC is classified into several subtypes: estrogen receptor (ER)-positive, progesterone receptor (PR)-positive, human epidermal growth factor receptor 2 (HER2)-positive, and triple-negative breast cancer (TNBC). The luminal subtype  \n(ER-positive and/or PR-positive) is the most common, whereas the HER2-positive subtype is characterized by rapid proliferation and responsiveness to HER2-targeted therapy (3) . Metastasis, which accounts for over 90% of cancer-related deaths, is a primary contributor to the high mortality rates associated with BC [4, 5] . The PI3K/ PTEN/Akt/mTORC1 signaling pathway plays a crucial role in BC metastasis [6–8], with mammalian target of rapamycin (mTOR) acting as a key regulator of cancer cell proliferation, angiogenesis, invasion, and adaptation to new environments [9–11] .  \nIn luminal and HER2-positive subtypes, mTOR activation is associated with tumor gr","cbCaiphpNKXeGua7","https://ap.wps.com/l/cbCaiphpNKXeGua7","pdf",367982,"English","# Abstract\n## Background\n## Methods\n## Results\n## Conclusions\n# Introduction\n# Materials and Methods","[{\"question\":\"What is the study’s primary purpose regarding mTOR?\",\"answer\":\"To assess the relationship between serum mTOR levels and metastasis in luminal breast cancer subtypes and evaluate mTOR as a predictive biomarker and potential therapeutic target.\"},{\"question\":\"How were serum mTOR levels measured and how was the cut-off determined?\",\"answer\":\"Serum mTOR levels were measured using a Human ELISA kit, and the optimal cut-off was determined using ROC curve analysis.\"},{\"question\":\"What results link mTOR levels to metastasis?\",\"answer\":\"Elevated serum mTOR levels (≥13.32 ng/mL) were significantly associated with metastasis (p\\u003c0.001), with particularly higher mTOR levels observed in HER2-positive cases.\"}]","mTOR Levels and Metastasis in Luminal Breast Cancer - Implications for Prognosis and Treatment | PDF",1790186733,15,[146,150,154,158],{"page_no":22,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/371948d22d128d2fa9dc9f6337582558.webp",983,1390,{"page_no":26,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/cb4be14d9e2a6e403da5def1fdbd51c4.webp",982,1388,{"page_no":30,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/a0de347a56e63fcb1fb6cce10e9ac74c.webp",981,1387,{"page_no":33,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/7e14e6d4fabc0fd982681513d9d807fc.webp",980,1385]